EXANE DERIVATIVES: TME position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on TME, newest first. How the timeline and the estimate are built.
EXANE DERIVATIVES held 0 TME shares at 2021-12-31 per its 13F-HR filed 2022-01-28.
the latest 13F is the newest step
- period ended2021-12-3113F 0 sharesChange vs previous 13F -5,100 shares
13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2021-09-3013F 5,100 sharesChange vs previous 13F 0 shares
0.01% of the 13F portfolio, value $36,972.
13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2021-06-3013F 5,100 sharesChange vs previous 13F 0 shares
0.02% of the 13F portfolio, value $66,400.
13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2021-03-3113F 5,100 sharesChange vs previous 13F -20,230 shares
0.03% of the 13F portfolio, value $104,494.
13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2020-12-3113F 25,330 sharesChange vs previous 13F -8,987 shares
0.15% of the 13F portfolio, value $487,327.
13F-HR 0001623883-21-000002 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2020-09-3013F/A 34,317 sharesChange vs previous 13F not available
0.17% of the 13F portfolio, value $506,786.
13F-HR/A 0001623883-20-000010 filed by EXANE DERIVATIVES
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).